Macular Edema and Macular Degeneration Market Forecast Analysis Through 2030 With Insights On Industry Expansion
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Forecasted Market Size Of The Macular Edema and Macular Degeneration Market Compare Between 2026 And 2030?
The macular edema and macular degeneration market has demonstrated robust growth in recent years. This market is projected to expand from $10.33 billion in 2025 to $11.03 billion by 2026, achieving a compound annual growth rate (CAGR) of 6.8%. Historically, this growth can be attributed to several factors including the rising prevalence of diabetes and retinal disorders, an aging population facing increased risks of vision impairment, the proven clinical efficacy of anti-VEGF injections, heightened awareness regarding macular diseases, and the expanding network of ophthalmology clinics.
The market size for macular edema and macular degeneration is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $14.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. Key factors driving this growth during the forecast period include a surging global diabetic population, increased screening initiatives for retinal conditions, a heightened need for less invasive eye procedures, broader access to sophisticated ophthalmic treatments, and greater healthcare expenditures dedicated to vision preservation. Significant trends identified for this period encompass the increasing embrace of anti-VEGF-based therapies, an escalating demand for prompt diagnosis and intervention, a wider application of combination drug and laser treatments, a heightened emphasis on addressing diabetic eye complications, and the expansion of outpatient and clinic-based eye care services.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp
Which Growth Factors Are Strengthening The Macular Edema and Macular Degeneration Market Landscape?
The expanding diabetes population is projected to stimulate the growth of the macular edema and macular degeneration market. Diabetes is a chronic medical condition characterized by elevated blood glucose (sugar) levels, which can damage the blood vessels in the eye, potentially causing macular edema and macular degeneration. For example, in June 2024, data from The National Health Service (NHS England), a UK-based publicly funded healthcare system, revealed that in 2023, the number of individuals identified with pre-diabetes by the NHS in England increased to 3,615,330, showing an 18% rise from 3,065,825 in 2022. Additionally, for those under 40, cases climbed by almost 25%, from 173,166 in 2022 to 216,440 in 2023. Thus, the increasing diabetes population is a significant driver for the growth of the macular edema and macular degeneration market.
How Is The Macular Edema and Macular Degeneration Market Examined Through Segment Analysis?
The macular edema and macular degeneration market covered in this report is segmented –
1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation, Subthreshold Laser Therapy, MicroPulse Laser Therapy
Which Trends Are Influencing The Expansion Of The Macular Edema and Macular Degeneration Market?
Major companies engaged in the macular edema and macular degeneration market are prioritizing the development of innovative products, like continuous-delivery ocular implants, to alleviate treatment burden, enhance patient adherence, and provide more consistent long-term therapeutic outcomes. These continuous-delivery ocular implants are compact, refillable devices situated in the eye that steadily release medication over several months, thereby assisting patients by lessening the requirement for frequent injections and delivering continuous, prolonged treatment for retinal diseases. For example, in February 2025, F. Hoffmann-La Roche Ltd, a biotechnology company based in Switzerland, obtained U.S. Food and Drug Administration (FDA) approval for Susvimo, a refillable ocular implant that administers the anti-VEGF drug ranibizumab for the management of diabetic macular edema (DME). Susvimo is engineered as a long-acting, surgically placed reservoir that continuously releases a tailored formulation of ranibizumab, thereby maintaining therapeutic drug levels for extended durations. Unlike standard anti-VEGF intravitreal injections which often necessitate monthly or bi-monthly dosing, Susvimo offers a refill-exchange interval of approximately six months, substantially decreasing the patient’s treatment burden. Its sustained-delivery mechanism boosts adherence, streamlines clinical procedures, and delivers durable anatomical and visual advantages for patients suffering from chronic retinal disease.
Who Are The Businesses Driving Activity In The Macular Edema and Macular Degeneration Market?
Major companies operating in the macular edema and macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Kodiak Sciences Inc., Opthea Limited, IVERIC bio Inc., Neurotech Pharmaceuticals Inc., Regenxbio Inc., Graybug Vision Inc., Clearside Biomedical Inc., Kubota Pharmaceutical Holdings Co Ltd, Acucela Inc., PanOptica Inc., Ocugen Inc.
Access The Complete Macular Edema and Macular Degeneration Market Report:
Which Region Has The Strongest Presence In The Macular Edema and Macular Degeneration Market?
North America was the largest region in the macular edema and macular degeneration market in 2025. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Macular Edema and Macular Degeneration Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp
Browse Through More Reports Similar to the Global Macular Edema and Macular Degeneration Market 2026, By The Business Research Company
Macular Edema And Macular Degeneration Global Market Report 2026
Age Related Macular Degeneration Global Market Report 2026
Retinal Disorder Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
